BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
Susan Bal(University of Alabama at Birmingham Hospital), Omar Nadeem(Harvard University), Larry D. Anderson(Dana-Farber Cancer Institute), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Tara Gregory(Colorado Blood Cancer Institute), Jesús G. Berdeja(Tennessee Oncology), Naomey Sarkis(Bristol-Myers Squibb (United States)), Michael R. Burgess(Bristol-Myers Squibb (United States)), Wei-Ming Kao(Bristol-Myers Squibb (United States)), Myo Htut(City of Hope), Hongxiang Hu(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Alok Shrestha(Bristol-Myers Squibb (United States)), Jinjie Chen(Bristol-Myers Squibb (United States)), Chaoqun Mei(Bristol-Myers Squibb (United States)), Luciano J. Costa(University of Alabama at Birmingham), Thomas G. Martin(University of Colorado Boulder), Allison Kaeding(Bristol-Myers Squibb (United States))
Cited by 6
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505